Tri Nguyen is a research scientist in academy. He have primarily studied/researched in bio-medicine for 8 years. He hold Ph.D degree since 2004. He has several publications in the field of oncology. He occasionally invests recently. His investment is focused on biotech-pharma companies which have potential pipelines for growing up. Twitter@ngktri
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
I am an individual investor in a quest to minimize portfolio rotation.
I am agnostic in terms of growth vs value, but lacking the time, the resources and (most importantly) the brains, I tend to look more among the latter set of opportunities.
I am professionally versed in the European upstream O&G arena, but skeptic on its future (and optimist about the clean-tech momentum of California).
One could argue I should have an edge in European stocks: I am from Spain and based in the UK, but like Buffett says, it's far better to buy a wonderful company at a fair price than a fair company at a wonderful price. So my portfolio is OW US and UW Europe.
N.B. If some of my comments are overly cynic, don't be offended, just an invitation to look after your $ more carefully.
Peter George Psaras, has been investing for over 40 years and has expertise in the following:
1) Quantitative Analysis
2) Qualitative Analysis
3) Macro Economic Analysis
4) Technical Analysis
5) Stock Market History
He is the CEO at Conservative Equity Investment Advisors, a registered investment advisor based in New York.
Capital Markets consultant and active investor in the emerging life science space. Tenured futures trader. Able to provide access to a pool of investors and traders throughout the US and UK. ProActive Capital, a capital markets advisory firm that makes direct investments and provides advisory services into public and private life science companies. Areas of focus include; capital introduction, shareholder management, communications and investor outreach.
Stockviews is a tool for amateur and professional investors. It aggregates stock opinions from a variety of sources, including Wall Street, Twitter, the financial press and 13F SEC filings. Algorithms are used to ensure the information is highly relevant to the decision-making process. This project is the creation of a professional fund manager who recognised there was a huge amount of information available on the web, but limited means to filter it in an effective way. Stockviews.com is due to launch towards the end of March.
Follow us on Twitter @StockViewsNews